ARTICLE | Company News
FDA approves Lilly's Olumiant for RA
June 1, 2018 5:02 PM UTC
FDA approved Olumiant baricitinib from Eli Lilly and Co. (NYSE:LLY) and partner Incyte Corp. (NASDAQ:INCY) to treat moderate to severe rheumatoid arthritis in patients who have responded poorly to one or more TNF antagonists.
Lilly intends to launch Olumiant this quarter. A Lilly spokesperson told BioCentury the drug's wholesale acquisition cost will be about $25,000 annually, noting that the WAC is 60% less than that of Humira adalimumab from AbbVie Inc. (NYSE:ABBV)...